Mode
Text Size
Log in / Sign up
Phase 4 Completed N=5 Basic Science

Intranasal Delivery of Testosterone and Its Effect on Doping Markers

Abuse of Anabolic Steroids
Source: ClinicalTrials.gov NCT02611154 ↗
Enrolled (actual)
5
Serious AEs
0.0%
Results posted
Mar 2017
Primary outcomePrimary: Steroid Levels in Urine Steroid Profile — 69.5773456; 138.0291641; 163.117081; 107.7160658 ng/mL
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

Hypothesis: Intranasal administration of exogenous testosterone results in a characteristic profile during anti-doping testing, which is different than the profile seen when testosterone is administered into muscle, on skin or under the tongue. Objective: The investigators aim to characterize the unique steroid doping profile following administration of intranasal testosterone to healthy, active volunteer subjects.

Outcome Measures

OutcomeResultp-value
PRIMARY
Steroid Levels in Urine Steroid Profile
69.5773456; 138.0291641; 163.117081; 107.7160658; 14.15587072; 21.42280994
SECONDARY
Number of Participants With Suspicious Steroid Profile in Urine Samples at Baseline
0; 0; 0; 0; 0; 0
SECONDARY
Testosterone Level in Blood as Measured for Safety
408.4; 373.4

Eligibility Criteria

Inclusion Criteria

  • Males between the ages of 18 and 35 years-old who participate in regular, moderate to high intensity physical activity will be recruited for the study.

Exclusion Criteria

  • Individuals below the age of 18 or greater than the age of 35 on the day of enrollment
  • Individuals who are in a Registered Testing Pool for anti-doping purposes, or individuals who for any reason could be subject to doping control testing.
  • Unwilling to provide blood or urine samples
  • Not actively exercising
  • Individuals with any history of cancer, cardiovascular disease, endocrine abnormalities, renal disease, hepatic disease, neurologic disease or any psychiatric history
  • Individuals with a history of nasal disorders, nasal surgeries, sinus surgeries, or sinus disease
  • Individuals that have a baseline hematocrit value above the normal range
  • Individuals that are diabetic or are currently taking a diabetic medication
  • Individuals that are currently using any WADA prohibited substances
  • Individuals that have recently used or currently using anabolic androgenic steroids
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02611154). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search